pharmaphorum2y
Novartis lines up Merck exec to replace R&D leader Jay Bradner
Jay Bradner, president of the Novartis Institutes for Biomedical Research (NIBR), is retiring from the position after seven years in the role, and will be replaced by Merck & Co R&D executive ...
Business Insider6y
Novartis is betting that AI is the 'next great tool' for finding new, cutting-edge medicines. Here's how the $220 billion drug giant is using it.
As president of the Novartis Institutes for BioMedical Research, or NIBR, Bradner leads the company's drug research and discovery. But, speaking at the World Economic Forum in Davos, Switzerland ...
pharmaphorum2d
AI helping us make smarter, faster decisions, says Novartis R&D chief
Then in October the company unveiled a major restructuring of its global R&D organisation, led from its headquarters in Basel, Switzerland and the Novartis Institutes for BioMedical Research (NIBR ...
WKRN-TV28d
IsomAb makes two key appointments; Dr Shi Yin Foo M.D. as Non-Executive Director and Dr Gary Burgess M.D. as Chief Medical Officer
She has been in executive roles at multiple biotechnology companies, including Novartis (NIBR), Cardioxyl Pharmaceuticals, Imara Therapeutics, Tiburio Therapeutics and Cydan II, and is currently ...